(megestrol acetate, USP)
MEGACE® (megestrol acetate, USP) Oral Suspension contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone.
MEGACE Oral Suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).
Media Articles Related to Megace (Megestrol)
Forensic investigations often use dead body feeding larvae
Source: Biology / Biochemistry News From Medical News Today [2014.07.28]
Non-biting blow fly Chrysomya megacephala is commonly found in dead bodies and is used in forensic investigations to determine the time of death, referred to as the post mortem interval.
Published Studies Related to Megace (Megestrol)
[Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss]. [2011.07.23]
BACKGROUND AND OBJECTIVE: Weight loss in patients with severe chronic obstructive pulmonary disease (COPD) is a prognostic bad factor. The objective of this study is to analyze the effectively of megestrol acetate (MA) to increase appetite of these patients... CONCLUSIONS: MA safely increases the body weight and the appetite in severe COPD patients with weight loss. MA improves blood gases and nutritional parameters and the sense of wellbeing, but it does not improve the respiratory muscular function or exercise tolerance. Copyright (c) 2010 Elsevier Espana, S.L. All rights reserved.
Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17beta-estradiol (NOMAC/E2): a double-blind, randomized study. [2011.06]
BACKGROUND Nomegestrol acetate/17beta-estradiol (NOMAC/E(2)) is a new monophasic oral contraceptive combining NOMAC (2.5 mg), a highly selective progesterone-derived progestogen, with E(2) (1.5 mg), which is structurally identical to endogenous estrogen... CONCLUSIONS The 24-day NOMAC/E(2) regimen was associated with greater inhibition of follicular growth and shorter duration of withdrawal bleeding than the 21-day regimen, suggesting the shorter pill-free interval results in a greater margin of contraceptive efficacy and tolerability, and fewer withdrawal symptoms.
Antiemetic activity of megestrol acetate in patients receiving chemotherapy. [2011.05]
PURPOSE: Several trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature. Our objective was to evaluate the antiemetic ability of megestrol acetate in patients receiving chemotherapy... CONCLUSION: Megestrol acetate was shown to be an effective antiemetic agent. Megestrol acetate might be a new antiemetic option for chemotherapy.
Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17beta-oestradiol: a double-blind, randomised, dose-finding pilot study. [2011.04]
OBJECTIVE: To explore the optimal dose of the progestogen, nomegestrol acetate (NOMAC), required in a monophasic oral contraceptive, in combination with 1.5 mg 17beta-oestradiol (E(2)), to inhibit ovulation... CONCLUSION: The dose of 2.5 mg NOMAC was confirmed to be optimal to inhibit both ovulation and follicular maturation. The antigonadotropic effect of 2.5 mg NOMAC was reinforced when combined with 1.5 mg E(2).
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. [2011.03]
Use of oral contraceptives (OC) that combine a progestogen with synthetic ethinyl estradiol (EE) is associated with increased risk of venous thromboembolism. NOMAC/E2 is a new monophasic OC that combines nomegestrol acetate (NOMAC), a highly selective progestogen, with 17beta-estradiol (E2)...
Clinical Trials Related to Megace (Megestrol)
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension [Terminated]
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg
dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with
varying degrees of renal impairment
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-Related Weight Loss [Completed]
Explore weight gain in HIV-positive patients who have weight loss associated with
AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either
megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate
oral suspension original formulation
Evaluating the Effect of Food on Absorption of Megace ES [Completed]
Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers [Not yet recruiting]
Phase I study of Megace F will be conducted to investigate pharmacokinetics and safety
compared to Megace OS.
Phase I study divided into 3 parts written as belows.
Part 1 Megace F in fasting volunteers vs Megace F in fed volunteers Part 2 Megace F vs
Megace OS in fed volunteers Part 3 Megace F vs Megace OS in fasting volunteers
Treatment of Cancer-Associated Anorexia Using Megestrol Acetate Concentrated Suspension [Terminated]
To compare the effect of megestrol acetate concentrated suspension and placebo on caloric
intake in patients with cancer-associated anorexia.
Reports of Suspected Megace (Megestrol) Side Effects
Abdominal Pain (16),
Cognitive Disorder (16),
Vaginal Haemorrhage (9),
Confusional State (6),
Mental Status Changes (4), more >>